Potential of combined ultrasound and microneedles for enhanced transdermal drug permeation: a review by Tao Han (1255185) & Diganta Das (1254000)
Page 1 of 54 
 
Potential of combined ultrasound and microneedles for 1 
enhanced transdermal drug permeation: A review 2 
Tao Han, Diganta Bhusan Das* 3 
Chemical Engineering Department, Loughborough University, Loughborough LE11 3TU, 4 
Leicestershire, UK 5 
(*Corresponding author; Email: D.B.Das@lboro.ac.uk) 6 
Abstract 7 
Transdermal drug delivery (TDD) is limited by the outer layer of the skin, i.e., the stratum 8 
corneum. Research on TDD has become very active in recent years and various technologies 9 
have been developed to overcome the resistance of the stratum corneum to molecular 10 
diffusion. In particular, researchers have started to consider the possibility of combining the 11 
TDD technologies in order to have further increase in drug permeability. Microneedles (MNs) 12 
and ultrasound are both promising technologies. They achieve enhancement in drug 13 
permeation via different mechanisms and therefore give a good potential for combining with 14 
each other. This review will focus on discussing the potential of this combinational technique 15 
along with other important issues, e.g., the mechanisms of ultrasound and MNs as it is these 16 
mechanisms which are coupled via the two systems (i.e. MNs and ultrasound). We discuss 17 
the possible ways to achieve this combination as well as how this combination would 18 
increase the permeability. Some of the undeveloped (weaker) research areas of MNs and 19 
sonophoresis are also discussed in order to understand the true potential of combining the two 20 
technologies when they are developed further in the future. We propose several hypothetical 21 
combinations based on the possible mechanisms involved in MNs and ultrasound. 22 
Furthermore, we carry out a cluster analysis by which we determine the significance of this 23 
Page 2 of 54 
 
combinational method in comparison with some other selected combinational methods for 24 
TDD (e.g., MNs and iontophoresis). Using a time series analysis tool (ARIMA model), the 25 
current trend and the future development of combined MNs and ultrasound are also analysed. 26 
Overall, the review in this paper indicates that combining MNs and ultrasound is a promising 27 
TDD method for the future. 28 
Keywords: Transdermal drug delivery, sonophoresis, microneedles, iontophoresis, chemical 29 
enhancers, permeability, autoregressive integrated moving average, cluster analysis 30 
1. Introduction 31 
Transdermal drug delivery (TDD) methods intend to deliver drug molecules to the blood 32 
circulation at a controlled rate for which the molecules need to pass through different sub-33 
layers of the skin. TDD is developing fast and there are now many approved drugs for TDD, 34 
e.g., nineteen (19) drugs have been approved by the Food and Drug Administration, USA  [1]. 35 
The potential of TDD for treating human diseases is also huge. For example, TDD can 36 
provide prolonged treatment time in the cure of chronic diseases while maintaining the 37 
permeation of the active drug molecules at a controlled level [2]. The diseases may be either 38 
psychological or physiological, and may need TDD ranging from nicotine patch for smoking 39 
cessation to the treatment of eczema [3, 4]. However, the full potential of TDD is not fully 40 
exploited yet, which is evidenced by the fact that new questions continue to be asked on how 41 
to develop the TDD methods further, for example, to resolve specific issues and/or 42 
incorporate the latest technological advances. For instance, it has been asked if it is possible 43 
to make functionalised delivery system for vaccines that can be applied in a simple way such 44 
as topical administration [5]. To develop a TDD method for clinical purposes, one may 45 
require a significant amount of finances and many technical impediments would need to be 46 
resolved [6]. For example, it is evident that the market of TDD products has developed very 47 
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fast and they were worth a market value of US $21.5 billion in 2010 which accounts for more 48 
than 12% of global drug delivery market. The development of the TDD market is predicted to 49 
reach US $31.5 billion by 2015 in which US $3 billion belongs to transdermal patch market 50 
[7]. However, the diversity of the drugs that could be delivered and various applications of 51 
these TDD techniques for treating human diseases are still limited.  52 
 53 
Despite the commercial successes of the TDD methods, further development and success of 54 
these methods cannot solely depend on the transdermal patches. Improvement on the drug 55 
delivery efficiency and increment on the numbers of applicable drug molecules need to be 56 
achieved in the future by extending the TDD technology in multiple ways. In these regards, 57 
one of the main technical obstacles that should be overcome is the low efficiency on 58 
delivering large molecules such as proteins, vaccines, and micro-particles [8] using the TDD 59 
methods. Microneedles (MNs) [9] and ultrasound [10] are two TDD techniques which work 60 
using different principles/mechanisms but they have shown great potential to remove this 61 
obstacle either on their own or in combination with each other. There are a number of 62 
publications now which have reviewed these two technologies on their own [11, 12, 13, 14, 63 
15]. There are also some recent studies where MN and ultrasound have been combined to 64 
increase skin permeability of large molecule [16, 17]. However, there is a lack of systematic 65 
review which discusses thoroughly the potential of combining MNs with ultrasound for 66 
enhanced drug permeation. Therefore, this review will focus on discussing the possible ways 67 
by which these two technologies could be combined. The first section of this paper will focus 68 
on explaining why the combination of MNs and ultrasound is important for TDD. The second 69 
and third sections will review the mechanisms of ultrasound and MNs, respectively, as these 70 
are the keys in the success of a TDD method that combines MNs and ultrasound. The fourth 71 
section will discuss the possible ways of combination and try to suggest what combinations 72 
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one may be interested in the future with the help of a cluster analysis. The last section of the 73 
paper is the conclusion section of the paper. The scope of this paper is discussed further in 74 
detail later in this section.  75 
1.1 Roles of TDD 76 
In order to provide further context to this review paper, we discuss the roles of TDD method 77 
briefly in this section. Not until the 1940s, has the TDD been specialized as one of the most 78 
essential drug delivery methods including the parenteral delivery (hypodermic injections) and 79 
oral formulations (solutions, suspensions, tablets and capsules) [18]. The main advantages of 80 
TDD over drug delivery through other routes are that: (a) TDD is user friendly, so that it can 81 
prevent needle phobia and avoid the pain perceived during the parenteral delivery [19], (b) 82 
TDD can dodge the gastrointestinal and liver metabolisms which are the most common issues 83 
in oral drug delivery [20] and, (c) TDD can provide long-term treatment without causing 84 
significant inconvenience, e.g., patients do not need to carry bulky medical instruments 85 
during the intravenous therapy which usually takes many hours [21]. In the past, the TDD 86 
methods mostly involved the uses of skin ointments and creams until a great progress was 87 
made in the 1980s when a transdermal patch was first introduced for the treatment of space 88 
motion sickness aimed at delivering scopolamine by attaching the transdermal patch on the 89 
back of the ear [22]. In general, the transdermal patches can prevent evaporations during 90 
treatment as well as achieve control rates of drug delivery [23]. However, their mechanism 91 
for drug delivery is based on passive diffusion. For this reason, the outermost layer of the 92 
skin, i.e., the stratum corneum (SC), restricts the choice of the drug molecule that can be 93 
administrated. For example, the molecular weight (MW) cut off for these molecules is 94 
generally taken to be under 500 Da [24] while their partition coefficient Kow should be 95 
between 1 to 5 [25, 26].  96 
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1.2 Different TDD technologies 97 
It is a matter of fact that the transdermal patch is a low efficient method in terms of drug 98 
permeability and area of skin covered by drug transport. However, there are a number of 99 
other technologies which particularly aim to increase drug transport rate and they may extend 100 
the diversity of the drug molecules that may be used in TDD (e.g., microneedles [27], 101 
sonophoresis [28] and iontophoresis [29]). All of these technologies are non-invasive or 102 
minimally invasive and, thus they provide painless drug administrations.  103 
 104 
The technologies that aim to enhance the permeability of the drugs through the skin as 105 
compared to transdermal patches alone can be grouped broadly according to the following 106 
five classifications: (i) methods that adjust the physicochemical properties of the drug 107 
molecules or increase the chemical potential of the drug solution to acquire better delivery 108 
rate, e.g., prodrug [30]; (ii) methods that tentatively alter the skin structure or modify the 109 
drug/skin partition coefficient to reduce the resistance of stratum corneum, e.g., chemical 110 
enhancers [31, 32]; (iii) methods that deliver drugs or microparticles directly into skin with 111 
the help of particle accelerator, e.g., gene guns [33, 34, 35, 36]; (iv) methods that use a 112 
gradient field (e.g., pressure gradient, electrical charge, any others) to induce convective flow 113 
increasing drug delivery rate, e.g., iontophoresis [37] and sonophoresis [38]; and, (v) methods 114 
that  physically disrupt or damage the skin to create new pathways which allow the drug 115 
molecules to be delivered through the skin barrier, e.g., MNs [39]. These five approaches are 116 
shown in more detail in Fig. 1. From the figure we can see that some TDD techniques may 117 
increase the diffusion rate via multiple mechanisms (sonophoresis, electroporation, etc.) 118 
while others may work similarly under the same categories. The combination of more than 119 
two or more than two techniques under the same category may not be able to yield a 120 
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promising permeability increment due to the possible redundancy/suppression of a particular 121 
mechanism in presence of another, e.g., microneedles and SC removal methods are both 122 
under category (iv) that aiming to bypass SC layer physically, thereby combining these two 123 
methods will be unnecessary. On the contrary, some TDD approaches indicate more potential 124 
for combinational methods because there are improved possibilities for them working in a 125 
synergetic way with another approach. Because the categories in Fig. 1 are subjectively 126 
divided, they are not necessarily able to provide every possible patterns of combination.  127 
 128 
Fig. 1 Current TDD technologies can be presented in five broad branches 129 
As stated earlier, the existing work in the literature suggests that it is possible to combine 130 
more than one method for enhancing drug permeability and there is a significant amount of 131 
work on different combinational approaches [40, 41]. However, it needs to be pointed out 132 
that the researches on the development of individual technology are very important for the 133 
development of the combinational methods because the researches on the individual method 134 
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can provide better understandings and stronger bases for the applications of these 135 
technologies. These improvements are crucial factors to ensure diversity and quality of the 136 
combinations. 137 
 138 
The ultrasound and MNs combination has covered four branches (categories ii, iii, iv and v) 139 
in the Fig. 1 which suggests that there could be much more possible forms of combination in 140 
the future. To have better understanding on the possible combinations between ultrasound 141 
and MNs, a detailed review based on the mechanisms of both technologies are necessary 142 
which has been carried out on following sections. In order to discover more opportunities in 143 
the ultrasound and microneedles combination, the main mechanisms of these two techniques 144 
will be reviewed individually. However, there are also many other minor factors among those 145 
mechanisms which could be important in some circumstances or will become significant 146 
factors when accuracy of the TDD is taken into account. Therefore, these factors and their 147 
main mechanisms will be discussed (fourth section).  148 
2. Ultrasound applications in TDD  149 
The ultrasound participated applications cover many cross-cutting research areas which 150 
include physics, chemistry, biology, engineering, and others. One of the main areas where 151 
ultrasound has been employed is the medicine, as exemplified by a large number of 152 
publications between 1975 and 2013 (Fig. 2). During this period, approximately 210,540 153 
publications have appeared which relate to the use of ultrasound in medicine alone whilst the 154 
total numbers of papers relating to all areas of ultrasound applications are approximately 155 
283,430. The number of papers of ultrasound applications for medicine only was 941 in 1975 156 
and it reached 13,470 in 2013 which suggests an average 7.25% increment in the number of 157 
publications each year.  158 
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 159 
Fig. 2 The numbers of publications of ultrasound for both applications in medicine and all 160 
other areas (all results searched using Scopus [42]). 161 
Generally, the ultrasound applications in medicine depend on the power and frequency of the 162 
ultrasound output [43]. The intensity of the ultrasound is a crucial parameter which 163 
determines its usage for either diagnostic or therapeutic purpose. The diagnostic ultrasound 164 
must have a relatively low intensity to reduce any adverse effect to human body whilst high 165 
intensity ultrasound can damage tissues via cavitation and high temperature. The ultrasound 166 
applications classified according to their frequencies and intensities shown in Table 1.  167 
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Table 1. The applications of ultrasound sorted by different parameters 168 
Diagnostic 
ultrasound 
(real time medical 
imaging [44]) 
Physiotherapeutic 
ultrasound 
(bone healing [45]) 
Sonophoresis 
(transdermal drug 
delivery [46]) 
High intensity 
focused ultrasound 
(ultrasound blade 
[47]) 
Intensity:                    Low                                                                        High 
1-18MHz 1-3MHz 20kHz-3.5MHz 1-5MHz 
Non-cavitation Cavitation involved 
Thermal effect:          Low                                                                        High 
 169 
According to Table 1, sonophoresis (or phonophoresis) can be defined as an ultrasound 170 
application which has sufficient intensity to reduce the resistance of skin but keeps the 171 
temperature within a safe range. The first reported application of sonophoresis was used to 172 
treat polyarthritis by using hydrocortisone ointment combined with ultrasound in 1950 [48]. 173 
Since then this method has been widely used in the treatment of many other diseases 174 
including bone joint diseases and bursitis [49]. Although this approach is recognized by 175 
scientists, a number of issues (e.g., how to choose the parameters of ultrasound) continue to 176 
pose problems in sonophoresis.  177 
 178 
Besides the intensity and frequency of ultrasound, there are other parameters such as the duty 179 
cycles of the ultrasound, the treatment time and, the distance between ultrasound transducer 180 
and target, which also need to be considered for specific ultrasonic application [50]. Although 181 
they are often treated as minor factors [51], their importance cannot be underestimated and 182 
could become more useful in the future. 183 
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2.1 Impediments in the development of sonophoresis based TDD methods 184 
There a number of inherent mechanisms in the sonophoresis based TDD based methods 185 
which affect their performances. These methods have been involved in a lot of branches in 186 
TDD research as discussed earlier. However, it seems that the sonophoresis research is still 187 
not very active if compared with other TDD methods. To illustrate this point clearly, we have 188 
carried out a time series analysis based on an autoregressive integrated moving average 189 
(ARIMA) model. We apply this analysis to illustrate the development of sonophoresis 190 
research over time. ARIMA is a common approach used for time series analysis of 191 
quantitative data and it can be used to determine trends of the data by evaluating the 192 
projection from past patterns. This approach can be particularly useful to model trends where 193 
the data have non-linear and fluctuating trends (such as the data in this work). ARIMA has 194 
been widely applied in social science areas to help people for making informed decisions. For 195 
example, the approach can help one (i) to find opportunities by analysing the market trends 196 
[52], (ii) to set right deposit rates in a bank by studying the money transaction data [53], (iii) 197 
to predict the traffic flow to help people to avoid traffic congestion [54]. At the moment, 198 
there is no such time series analysis for the trend of sonophoresis or MNs research. ARIMA 199 
uses univariate Box-Jerkins models which imply that only the past values of the variables are 200 
involved in the analysis and it does not consider data from other series [55]. The model 201 
consists of two parts: autoregressive (AR) and moving average (MA) which can be chosen 202 
together or individually depending on the modelled situation. The model applied for the 203 
purpose of this paper is MA (1) which means no AR method is employed. The number in the 204 
brackets indicates an order of the algorithm.  205 
 206 
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For the time series analysis, the data acquired from scientific paper database are differentiated 207 
twice with respect to time to achieve a stable model, which provides a time series constant for 208 
the data. In the present case, the estimated time series constant was 2.029. MA (1) model is 209 
then employed to fit the trend of sonophoresis publications per year (Fig. 3). The fit and 210 
forecast results using the MA (1) model are shown in Fig. 3.  The predicted results on the 211 
number of publications in year 2020 are 60 which suggest a slight increment of 1.08% per 212 
year from the year 1970. Although the ultrasound technology is well understood, the results 213 
of this analysis shows that the development of sonophoresis is relatively slow and, there is no 214 
sudden increase or decrease in its interests as it may happen in many other methods or 215 
techniques. The number of publications on sonophoresis research has an averaged increment 216 
of 9.05% per year from 1970 to 2013. We believe there are two main reasons that have led to 217 
this slow growth as discussed below.   218 
 219 
Firstly, the sonophoresis based TDD methods are not supported by well-developed theory. 220 
For instance, the current theoretical description of the ultrasound assisted molecular diffusion 221 
and convection is simply an extension of the hindered diffusion theory as shown in Equation 222 
(1) [56]:  223 
log𝑃𝑑𝑑𝑑𝑑+𝑐𝑐𝑐𝑐𝑈𝑈 = log 𝑃𝑃1 − exp (−𝑃𝑃) + log � 𝑘𝑘2𝑧2𝐹𝑐𝑑𝑐𝑐𝑃0 𝐷𝑝∞𝐻(𝜆𝑝)𝐷𝑑𝑐𝑐∞ 𝐻(𝜆𝑑𝑐𝑐)� + log𝑅 
 
 (1) 
Where P is the drug permeability [m/s], Pe is the Peclet number [-], k is Boltzmann constant 224 
[J/K], T is the absolute temperature [K], z is the electrolyte valence [-], F is the Faraday 225 
constant [C/mol], c is the electrolyte molar concentration [mol/m3], e is the electronic charge 226 
[C], D is the diffusion coefficient [m2/s], H(λ) is the hindrance factor [-] and R is the skin 227 
resistivity [Ω∙m]. The size and electrical properties of the molecules have been considered in 228 
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this model, but there is little or no theoretical development work on the effects of the 229 
modification to the skin due to cavitation effect which is the main factor that sonophoresis 230 
contributes to TDD. Well-developed theoretical descriptions of various mechanisms in 231 
sonophoresis based TDD are important not only for its further development and research but 232 
also for understanding the experimental data and combining ultrasound to other TDD 233 
methods.   234 
 235 
Fig. 3 Fit and forecast results of the trend of sonophoresis publications using MA (1) model 236 
developed in MATLAB (keywords for search: sonophoresis/phonophoresis using Scopus 237 
[42]).  238 
Secondly, it seems that the researches on sonophoresis experiments involving drug 239 
permeability are somewhat chaotic and lack consistency. For example, the skin samples used 240 
in the experiments may lack a consistent quality and standard. Factors such as imperfections 241 
in skin samples, skin thickness variations, different sampling areas of the skin, different skin 242 
types, etc. also affect the drug permeability especially in the transport of large molecules. 243 
Furthermore, the uncertainties in the ultrasound system may alter the diffusion results. These 244 
uncertainties are included in the performance of the ultrasound system which needs to be 245 
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acquired using a hydrophone or force balance, and other details of the ultrasound setup (e.g., 246 
parameters such as distance of the ultrasound horn to skin surface and localized transport 247 
regions measurement [57]). Additionally, the significance of different mechanisms is not well 248 
understood and they must be determined. As mentioned earlier, sonophoresis includes several 249 
different mechanisms, all of which contribute to the molecular diffusion. The same 250 
ultrasound output, drug molecules and skin samples under different experimental conditions 251 
may show different diffusion results for ignoring some minor factor [58, 59]. Thermal effect, 252 
acoustic streaming and other phenomena can be significantly magnified due to those 253 
unnoticed factors varying the diffusion results. However, these factors are impossible to 254 
quantify separately in practice. Therefore, the overall progress of the research which 255 
particularly employs experimental methods seems to be slow. An illustration of percutaneous 256 
delivery of common drug molecules (MW are arranged from low to high) enhanced by 257 
sonophoresis is shown in Table 2. The table presents different diffusion results of a number 258 
of drug molecules. Even though all the experimental results have shown permeability 259 
increases, the data need to be carefully used in the context of sonophoresis. Therefore, the 260 
researchers have to ignore the less significant mechanisms in order to combine the 261 
sonophoresis to other TDD methods. To extend the combination range of sonophoresis and to 262 
increase the quality of combinations, sonophoresis experiments must be regulated and more 263 
elaborative experiments in consideration of the minor mechanisms must be executed.  264 
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Table 2. Ultrasound enhanced diffusion experiment data of selected compounds (mannitol, sucrose, cortisol, calcein, inulin, and insulin). 
Solute 
property 
Main 
experimental 
apparatus 
used 
Skin 
type 
Frequ
ency  
(MH
z) 
Intensit
y 
(W/cm2
) 
Exposure 
conditions 
Composition 
of donor 
solution in 
experimental 
apparatus 
Receiving 
solution  in 
experimental 
apparatus 
Analytical 
apparatus 
Temp. 
(̊C) 
Data analysis Result summary 
Mannitol 
 
MW: 182 Da 
Log K o/w = -
3.10 
US 
transducer; 
Franz 
diffusion cell 
In vitro 
hairless 
male 
Wistar 
rats skin 
250-300g, 
aged 4-5 
months 
1.1 0.1 
 
2.0 
CW 
(5 min) 
pre-
treatment 
5% v/v [14C] 
mannitol 
dissolved in 
100ml 
ethanolic 
solution 
24-33ml distilled 
water, 1.1ml 
aliquots were 
withdrawn every 
30min within 5h 
Liquid 
scintillation 
counter, 
thermocouple, a 
camera attached 
to a microscope 
(×125) 
Receptor 
solution: 37 
Mean± S.D. 
over 5h 
Mean flux of radiolabeled [14C] mannitol under US 
treatment of 0/0.1/2 W/cm2 are: 90.51±19.51/not 
detectable/375.7±53.21 pmol/cm2/h respectively; 
Not detectable because mannitol is mainly 
mediated via transfollicular pathway, but under 0.1 
W/cm2 US the sebaceous sebum is released into 
hair follicle shaft. For histological results, see Fig. 
3 in the original paper [60] 
Drugs applied 
to test sites 
followed by 
ultrasonic gel 
In vivo on 
the upper 
back of 
hairless 
SD rat 
200-300g 
1.0 1.5 CW 
(3 min) 
pre-
treatment 
1µCi/µl D-
[3H]mannitol 
saturated with 
unlabelled D-
mannitol in 
20µl 90% 
ethanol and 
10% water 
Urine in bladder 
collected using 
catheterization 
every 15-30 min 
within 2h 
Liquid 
scintillation 
counter 
Room 
temperature 
Mean± S.E.M. 
and student’s t 
test, P<0.05 
over 5h 
Mean secretion rate of radiolabeled [3H] mannitol  
shows 20-fold higher in the US treated group (n=4) 
than in the controls (n=12); for detailed data see 
Fig. 1 in the original paper [61] 
Modified 
Franz 
Freshly 
excised 
1.1 1.5 CW 
(20 min) 
5µCi/ml 
[3H]mannitol 
15 ml 0.9% 
normal saline, 
Liquid 
scintillation 
Receptor 
solution: 29-
Mean± S.E.M. 
calculated over 
Mean flux with and without US are 0.4±0.15 (n=4) 
and 0.5±0.15 (n=4) pg/cm2/h, respectively.  For 
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diffusion cell; 
US transducer 
(90% 
efficiency) 
surgical 
human 
skin 
pre-
treatment 
saturated in 3 
ml 0.9% 
normal saline 
500µl samples 
retrieved 
regularly 
 
counter, light 
and electron 
microscopy 
31, 
circulation 
Jacket: 32 
24h 
 
histological results see Fig. 1 and 2 in the original 
paper [62] 
In vitro 
hairless 
mice aged 
6-7 weeks 
Mean flux with and without US are 44.0±10.6 
(n=5) and 27.1±5.5 (n=9) pg/cm2/h, respectively. 
For histological results see Fig. 1 and 2 in the 
original paper [62] 
Sucrose 
MW: 342 Da 
Log Ko/w = -
3.70 
Franz 
diffusion cell, 
sonicatortest 
by a 
hydrophone, 
nylon mesh 
Epidermis 
heat 
stripped 
from 
human 
cadaver 
skin 
0.02 0.125 DC:10 
Length 
100ms 
(60 min) 
pre-
treatment 
1µCi/ml 
radiolabelled 
sucrose in a 
mixed solution 
(PBS 
0.01mol/l, 
NaCl 0.137 
mol/l) 
15.8ml 0.01mol/l 
PBS mixed with 
0.137mol/l NaCl  
Thermocouple, 
scintillation 
counter, light 
microscope 
(×40) 
Room 
temperature, 
no 
significant 
increasing 
during 
experiment 
(<2 ̊C) 
One value 
calculated at 
steady-state 
The result is given by permeability P=VΔC/(ACdτ), 
where V is the volume of the receiver 
compartment, A is the skin area (3.14 cm2),  ΔC is 
the measured concentration increase of the solution 
in the receiver compartment over a time period τ 
and Cd is the concentration of the solution in the 
donor compartment. The passive and  sonophoretic 
permeability are 5.2×10-6 and 0.026 cm/hr, 
respectively. For histological results see Fig. 3 in 
the original paper [63] 
US 
transducer; 
Franz 
diffusion cell  
In vitro 
hairless 
male 
Wistar 
rats skin 
250-300g, 
aged 4-5 
months 
1.1 0.1 
 
2.0 
CW 
(5 min) 
pre-
treatment 
5% v/v 
[14C]sucrose 
dissolved in 
100ml 
ethanolic 
solution 
24-33ml distilled 
water, 1.1ml 
aliquots were 
withdrawn every 
30min within 5h 
Liquid 
scintillation 
counter; 
thermocouple; a 
camera attached 
to a microscope 
(×125) 
Receptor 
solution: 37 
Mean± S.D. 
over 5h 
Mean flux of radiolabeled [14C] sucrose under US 
treatment of 0/0.1/2 W/cm2 are 11.49±3.01/not 
detectable/51.36±2.62 pmol/cm2/h, respectively. 
For histological results see Fig. 3 in the original 
paper [60] 
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Cortisol 
(Hydrocortis
one) 
MW: 362 Da 
Log K o/w = 
1.61 
US transducer 
combined 
with 
iontophoresis 
devices (5mA 
pre-treatment 
for 20 min) 
In vivo 
patients 
with 
unilateral 
carpal 
tunnel 
syndrome 
1.0 0.5-0.8 DC: 20 
Length 
4ms 
(3-6min) 
pre-
treatment 
25 mg clinic 
use 
hydrocortisone 
acetate 
n/a Pain intensity 
rated on 10 
levels called 10 
points Visual 
Analog Scale 
(VAS) 
Room 
temperature 
Mean± S.D. 
Wilcoxon 
signed-ranks 
test, P<0.05 
Group 1 (early stage of the disease), VAS 
before/after treatment: 7.4±0.5/1.8±1.9; 
Group 2 (moderate stage), VAS before/after 
treatment: 8.1±1.1/1.8±1.5; 
Group 3 (advanced disease stage), VAS 
before/after treatment: 8.0±1.2/4.2±1.9 [64] 
A 23-gauge 
butterfly 
catheter into a 
cubital fossa 
vein; US 
transducer 
In vivo 16 
human, 
aged 
between 
18-33 
(𝑋�=25, 
SD=2.74 
) 
1.0 1.0 CW 
(5 min) 
30 ml 
aquasonic gel 
for control 
group; 30ml 
10% 
hydrocortisone 
gel for 
experimental 
group 
5 cc blood 
sample was 
drawn followed 
by 2 cc saline 
flush in different 
time point 
Centrifuge; 
cortisol assay 
(0.45 µg/l 
sensitivity) 
Body temp. 
& blood 
sample 
clotted at 
room temp. 
Two-way 
ANOVA, 
P<0.05 over 30 
min time 
period 
The serum cortisol levels between US alone and 
hydrocortisone phonophoresis are:  
1. 10 min before US treatment: 9.7±4.1&10.1±2.9 
µg/dl;  
2. Immediate after US treatment: 8.2±4.2&8.8±3.5 
µg/dl;  
3. 5 min after US treatment: 8.2±3.8&9.4±3.5 
µg/dl;  
4. 15min after US treatment: 7.6±3.6&8.0±.3 µg/dl. 
Four subjects reported intolerable heating [65] 
Modified 
Franz 
diffusion cell; 
US transducer 
(90% 
efficiency)  
Freshly 
excised 
surgical 
human 
skin 
1.1 
 
1.5 
 
CW  
(20 min) 
6µCi/ml 
[3H]hydrocorti
sone saturated 
in 3 ml 0.9% 
normal saline 
 
15 ml 60% saline 
solution, 20% 
PEG 400 and 
20% ethanol, 
500µl samples 
retrieved 
regularly with 
equal 
Liquid 
scintillation 
counter; light 
and electron 
microscopy 
Receptor 
solution: 29-
31, 
circulation 
Jacket: 32 
Mean± S.E.M. 
calculated over 
24h 
 
Mean flux with and without US are 3.5±1.3 (n=5) 
and 3.0±0.6 (n=5) pg/cm2/h, respectively.  For 
histological results see Fig. 1 and 2 in the original 
paper [62] 
In vitro 
hairless 
mice aged 
Mean flux over 24h with and without US are 
46.8±4.6 (n=5) and 40.4±7.2 (n=5) pg/cm2/h 
respectively. For histological results see Fig. 1 and 
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6-7 weeks compensation 2 in the original paper [62] 
Modified 
Franz 
diffusion cell; 
US transducer 
(10min 
recalibration 
/h);  
In vitro 
intact 
Wistar 
rats skin 
250-300g, 
aged 4-5 
months, 
frozen in  
-20̊C up 
to 1 
month 
1.1   
 
3.3 
2.25 
 
2.25 
CW 
switched 
off for 10 
min 
following 
each 50 
min  over 
4h period 
1µCi/µl [3H] 
hydrocortisone 
dissolved in 
100µl 5% 
ethanol 
solution, 1% 
v/v chemical 
enhancers (if 
needed) 
applied 1h 
before (azone 
or oleic acid) 
5% aqueous 
ethanol, 1.1ml 
samples 
retrieved every 
30min with 
equal 
compensation 
Hydrophone; 
radiation force 
meter; 
thermocouple; 
liquid 
scintillation 
counter 
Circulation 
Jacket: 28 
temp. of 
skin surface 
see Fig. 
3&4 in 
original 
paper 
Mean± S.E.M. 
derived from 
linear 
regression 
analysis 
between 150-
300 min 
Mean flux: control/1.1MHz/3.3MHz are 
0.0073±0.0105/0.0133±0.0016/0.0160±0.0052 
pmol/cm2/h respectively; Oleic acid/Oleic 
acid+1.1Mhz are 0.0494±0.0092/0.0583±0.0029 
pmol/cm2/h respectively; 
Azone/Azone+1.1MHz/Azone+3.3MHz are 
0.0407±0.0054/0.1021±0.0125/0.0953±0.0172 
pmol/cm2/h respectively [66] 
3.3 0.75 
 
2.25 
 
2.25 
CW or 
DC: 33.3 
(Length 
2ms 
interval as 
above 
over 4h 
period) 
Mean flux of Azone-pretreated skin: CW 
0.75W/CW 2.25W/pulsed 2.25W are 
0.0388±0.0105/0.0378±0.0766/0.0540±0.0124 
pmol/cm2/h respectively [66] 
US 
transducer; 
Franz 
diffusion cell;  
In vitro 
hairless 
male 
Wistar 
rats skin 
250-300g, 
aged 4-5 
months 
1.1 0.1 
 
2.0 
CW 
(5 min) 
5% v/v 
[3H]hydrocorti
sone dissolved 
in 100ml 
ethanolic 
solution 
24-33ml 5% v/v 
aqueous ethanol, 
1.1ml aliquots 
were withdrawn 
every 30min 
within 5h 
Liquid 
scintillation 
counter; 
thermocouple; a 
camera attached 
to a microscope 
(×125) 
Receptor 
solution: 37 
Mean±S.D. & t 
test, P<0.0208 
over 5h 
Mean flux of radiolabeled [3H]hydrocortisone 
under US treatment of 0/0.1/2 W/cm2 are: 
0.105±0.023/0.0478±0.006/0.81±0.14 pmol/cm2/h 
respectively. For histological results see Fig. 3 in 
the original paper [60] 
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Calcein 
MW: 623 Da 
Log K o/w= 
1.56 
Sonicator; 
Custom-made 
vertical glass 
diffusion cells 
In vitro 
full-
thickness 
skin from 
porcine 
ears 
0.02 15 DC:10 
(2 hours) 
200mg calcein 
in 11ml PBS 
at pH 7.4 
38 ml PBS at pH 
7.4 
Confocal 
microscope 
Room 
temperature 
n/a There is no quantitative data in this research. 
However, it is using cross-sectional view of the 
skin (confocal images) to show the permeation of 
calcein with/without ultrasound treatment for 2 
hours duration within a 20 µm depth. It suggests 
that some areas showed great increment of 
permeation of calcein after the ultrasound 
treatment while some areas did not [67] 
Three 
separate US 
Systems; 
diffusion cells 
In vitro 
back and 
flank skin 
of female 
Yorkshire 
pigs 
0.02 
 
0.04 
 
0.06 
 
 
7.5 DC:50 
(length 
5s) 
0.2% w/v 
calcein in 
2.5ml PBS 
12 ml PBS, 
sampled at 2 h 
intervals 
between 18 and 
26 h 
UV–visible 
spectrophotomet
er absorbance 
wavelength: 494 
nm 
Room 
temperature 
25°C 
Mean± 
S.D. over 8 
hours 
The ultrasound treatment time varies according to 
when the electrical currents reach 225/275/335 µA. 
The results show that permeability is not affected 
by either electrical resistance or frequency change. 
The scales of permeability for passive/LTRs/non-
LTRs/total are 1×10-6/10-2/10-5/10-3 cm/h, 
respectively [68] 
custom-built 
US 
transducer; 
diffusion cells 
In vitro 
male 
WBN/ILS
-Ht strain 
hairless 
rats 
0.041 0.06 
 
0.12 
 
0.3 
 
CW 
(2 hours) 
1mM calcein 
in 10ml PBS 
at pH 7.4 
22 ml PBS, 
Sampled at 30 
min intervals 
between 12 and 
14 h 
Spectrofluorome
try excitation 
wavelengths: 
488 nm 
Room 
temperature 
Mean± 
S.D. over 2 
hours 
After 12 hours of passive diffusion, ultrasound is in 
turn applied for 30min to each at 0.06, 0.12, 0.3, 
0.06 W/cm2 for a total 2 hours. The flux increments 
from a base 1.1×10-2 nmol/cm2/h are 120, 8900, 
23000,5100 folds, respectively [69] 
Inulin 
 
MW: 5.0k Da 
 
Drugs applied 
to test sites 
followed by 
ultrasonic gel;  
In vivo on 
the upper 
back of 
hairless 
1.0 3 
 
 
 
DC: 80 
(5 min) 
0.22µCi/µl 
[3H]inulin 
saturated with 
unlabelled 
Urine in bladder 
collected using 
catheterization 
every 15-30 min 
Liquid 
scintillation 
counter 
Room 
temperature 
Mean± S.E.M. 
& Student’s t 
test, P<0.05 
over 2 hours 
Mean secretion rate of radiolabeled [3H]inulin 
shows 5 times higher in the US treated group (n=4) 
than in the controls (n=4), for detailed data see 
Fig. 2 in the original paper [61] 
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SD rat 
200-300g 
 
 
 
 
 
inulin in warm 
water 
 
 
 
 
within 2h 
Flanged glass 
cylinder 
glued on the 
rat’s shaved 
lateral flank 
In vivo 
Sprague 
Dawley 
rat of 
either sex, 
PBS 
hydrated 
for 1 h 
0.02 7 DC: 50 
length 5s 
(2 min) 
10 µCi/mL 
radiolabeled 
inulin in 2ml 
PBS 
Urine in bladder 
measured every 
30min for 5h 
Means only, no 
SD data 
available, 5 
hours 
Mean secretion rate of radiolabeled inulin 
before/after the ultrasound treatment are 7.4×10-6 
cm/h and 1.5×10-4 cm/h, respectively [70] 
Insulin 
 
MW: 5.8k Da 
 
Flanged 
plastic 
cylinder was 
glued to 
animal’s 
abdomenand 
sonicator 
 
In vivo 
hairless 
rats 
280±20g, 
aged 8-10 
weeks 
0.02 2.5 
 
5.0 
 
10.0 
DC: 10 
length 
0.1s (60 
min) 
3ml of insulin 
solution at a 
concentration 
of 100 U/ml 
 
0.6ml blood 
samples from 
jugular vein 
were 
immediately 
centrifuged and 
the serum was 
collected  
 
Thermocouple;  
biochemistry 
analyser (using 
glucose oxidase 
method) 
Donor 
solution: 27, 
animals’ 
body 
temperature: 
38 
One-factor 
ANOVA 
analysis, 
P<0.05 over 60 
min 
Blood glucose level of control group is 12.60±2.07 
mmol/l, the initial and after US treatment for 2.5W, 
5.0W, 10.0W are: 
12.91±1.68&11.22±1.71/12.20±0.60&10.65±6.22/
12.33±0.67&7.46±2.95 mmol/l, respectively [71] 
2.5 DC: 
10/20/30 
length 
1.6s (60 
min) 
Blood glucose level of control group is 12.60±2.07 
mmol/l, the initial and after US treatment for 
DC=10/20/30 are: 
12.91±1.68&11.22±1.71/11.84±1.38&9.79±2.89/1
0.62±0.88&4.91±2.77 mmol/l respectively [71] 
2.5 DC: 40 One-factor Blood glucose level of control group is 12.60±2.07 
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Note: CW = continuous wave; DC = duty cycle; PBS = phosphate buffered saline; S.E.M. = standard error of the mean; SD = standard deviation.
length 
0.2/1.6/3.
2s (15 
min) 
ANOVA 
analysis, 
P<0.05 over 15 
min 
mmol/l, the initial and after US treatment for pulse 
length=0.2/1.6/3.2 are: 
12.46±0.63&11.56±1.95/12.38±0.67&6.43±3.16/1
3.41±1.23&5.11±1.45 mmol/l respectively [71] 
 
 
 
1 mm thick 
water 
tight standoff 
arranged 
between the 
axillary area 
of the pig and 
the array 
In vivo 
Yorkshire 
pigs 
(100–140 
lbs) 
0.1 DC: 20 
Length 
200ms 
(60 min) 
100 U/ml 
insulin filled 
in 1 mm thick 
water-tight 
standoff 
0.3 ml blood 
samples from 
the ear vein 
every 15 min 
for 90 min 
 
Blood glucose 
monitoring 
System 
Room 
temperature 
One-factor 
ANOVA 
analysis, 
P<0.05 
for both 60 and 
90 min 
Blood glucose level before experiment is 146±13 
mg/dl (n=6); Control group increased 31±21 mg/dl 
(n=3) after 90 min; US treatment group decreased 
71±5 mg/dl (n=3) from beginning at 60 min and 
decreased 91±23 mg/dl (n=3) from beginning at 90 
min [72] 
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2.2 Thermal effect of sonophoresis 
The most obvious phenomenon during the sonophoresis treatment is the thermal effect and it 
is particularly relevant when using high frequency. The absorption of the sound in skin 
increases as the ultrasound frequency goes up, which means that the energy would be stored 
in skin rather than transmit through [73, 74]. The rise in the temperature of the skin increases 
the kinetic energy of the drug molecules which have a positive effect on the drug diffusion 
rate. However, the intensity in the application of sonophoresis is usually low; therefore, the 
thermal effects on the kinetics energy of the drug molecule and hence the drug permeability 
is not significant. For example, when 1.5 W/cm2 ultrasound was applied on hairless rat, the 
temperature change is found to be only around 1-2oC [61]. If the temperature increases 
significantly due to ultrasound treatment, it can cause skin injury. In particular, it has been 
reported that when the temperature reaches 43°C and maintains this temperature for 60 
minutes or longer, the cellular reproduction may be restrained [75]. Although the thermal 
effect generated by ultrasound is the most basic phenomenon due to energy gain/loss, it has 
the potential to increase and control the drug diffusion rate when combined with MNs, 
particularly, dissolving MNs. We discuss this point further in section 4.   
2.3 Convection in acoustic streaming 
Another ultrasound related phenomenon is termed as acoustic streaming which is a kind of 
fluid flow driven by the pressure gradient and generated by acoustic field [76]. The 
permeability enhancement due to acoustic streaming is hard to define but its importance is 
realized by the scientific community [77]. Different effects of the acoustic streaming can be 
identified by Reynolds number of the flow. With low Reynolds number, Lighthill [78] has 
described the relationship between the net force of unit volume Fj [N/m3] and forces that 
generated by the momentum flux ρ0uiuj (Reynolds stress) [N/m2], the pressure p [N/m2] and 
the viscosity µ [N∙s/m2]. The mathematical definition is given:  
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𝑭𝑗 = 𝜌0 �𝒖�𝑑 𝜕𝒖�𝑗𝜕𝑥𝑑� + 𝜕𝒑�𝜕𝑥𝑗 − 𝜇∇2𝒖�𝑗  (2) 
Where ρ0 is the density of the volume of the fluid [kg/m3], and u is the velocity vector [m/s]. 
As evident from the first two terms on the right hand side, the Reynolds stress and pressure 
gradient affect the net force in the tissue positively (the term in left hand side of the equation). 
But, as shown by the third term on the right hand side, higher fluid viscosity results in lower 
net force which indicates that the ultrasound field can apply higher forces on the flow in a 
less viscous solution. Tachibana [79] shows that the diffusion of lidocaine under the same 
ultrasound condition is higher when it is in the aqueous formulation instead of a gel. 
Therefore, the permeability enhancement caused by ultrasound generated force was 
experimentally proven. The phenomenon was successfully extended by applying this 
mechanism on highly aqueous tissues. Lewis [80] applied 1.58 MHz ultrasound on brain and 
avian muscle tissues, and report that the enhancements of Evans blue dye are 5.6 fold and 2.2 
folds, respectively. Using the experimental set up in Fig. 4, Cheung [81] has demonstrated 
that under 3 MHz ultrasound treatment the permeability of bovine serum albumin (BSA) 
increases 1.6 fold in intrascleral delivery.  
 
Although the researches on using acoustic streaming at low Reynolds numbers have shown 
increment on diffusion rate in soft tissues, the permeability enhancement on viable epidermis 
and dermis is still relatively unknown. As well known, viable epidermis and dermis of the 
skin are the most relevant skin layers for MN application as the MNs pierce the SC and 
deliver the drugs in the skin layers below the SC. However, it is logical to state that there are 
good potential for combining ultrasound with solid or hollow MNs because the MNs can 
create channels that reach viable epidermis. As such the ultrasound may reach the lower 
layers of the skin and help increase drug permeability in these skin layers. This combination 
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of TDD methods should be able to provide higher diffusion rate in comparison to sole MNs. 
There are some other mechanisms caused by acoustic streaming at high Reynolds numbers 
which are also important. These mechanisms will be discussed in sections 2.4-2.6. 
 
Fig. 4 The setup of ultrasound enhanced intrascleral delivery 
2.4 Acoustic cavitation in high frequency sonophoresis 
Acoustic streaming can produce different mechanisms in sonophoresis. The most important 
mechanism is acoustic cavitation (bubbles) which is generated in the liquid within or out of 
the skin. When ultrasound waves keep compressing and tensing the liquid in the tissue, the 
local pressure of liquid falls below vapour pressure, and therefore, the cavitation occurs. The 
cavitation can be divided into two types: stable and inertial discriminated by how long can 
the bubbles survive [82]. Frequency, intensity and duty cycles are used to control the 
cavitation types to achieve different applications. The cavitation generated during high 
frequency ultrasound treatment is much smaller in size as compared to those from the use of 
low frequency ultrasound. The relationships between the frequency and the bubble radius are 
presented by Gaertner [83]:  
Rabbit 
eyes 
4ml 0.1% FITC-
BSA solution 
0.05W/cm2, 3MHz 
continuous ultrasound 
     
Plastic 
container 
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𝑓(∅) = 1/ �sin3 ∅ [−(sin4 ∅ + sin2 ∅)(𝑝𝑅0 + 3𝛼) − 𝑝𝑅0]12� 
 
 (3) 
∅ = arcsin(𝑅0/𝑅)12 
 
 (4) 
Where f is the frequency of the ultrasound [Hz], R0 is the nucleus radius [m], α (surface 
tension) is a constant related to the medium [N/m] and R is the radius of the bubble [m] under 
pressure p [N/m2]. The equation indicates that the ultrasound frequency f is inversely related 
to the radius of the bubble R. The equation has also suggests that cavitation could be 
generated inside the skin or simply within the SC layer if the frequency is high enough  
2.5 Rectified diffusion 
Due to the relationship between frequency and bubble radius, the most important phenomena 
in high frequency sonophoresis, which is called rectified diffusion (Fig. 5), has been revealed 
by Blake [85]. The mechanism can be explained as follows. On the positive pressure half-
cycle (the local pressure increased under the ultrasound field) the gas in a small bubble will 
be compressed, the shell becomes thicker as a result the concentration gradient decreases 
because the bubble absorbs more drugs from surrounding environment. Some gas then 
diffuses outwards from the core of the bubble into the liquid. On the contrary, during the 
negative half-cycle of pressure, the surface of the bubble is expanded which makes it much 
larger than the compressed bubble. However, these two rates are not equal as the surface area 
of the bubble is greater during the negative (tension) half-cycle, and as diffusion rates are 
proportional to the exposed area, the bubble must gain some gas over a complete cycle [86].  
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Fig. 5 A schematic diagram of rectified diffusion [87]  
In the process of the rectified diffusion, the bubbles generated by cavitation are pushed by the 
Bjerknes force under acoustic pressure gradient to move downward [88]. The Bjerknes force 
is generated under the acoustic field which directly increases the diffusion rate of the drug 
molecules. It can then push the bubbles forward, thereby, increasing the diffusion rate. The 
basic expression of Bjerknes force is shown as: 
𝐹 = −〈𝑉∇𝑝〉 (5) 
Where < > denotes the average over one acoustic period, V is the volume of the bubble and p 
is the acoustic pressure. This equation can be further extended to define the Bjerknes force at 
any location r and time point t [89]: 
𝑭𝑩𝑑 = −𝐺𝑑(𝐫) 1𝑘� 𝑉(𝐫, 𝑡)cos[𝜔𝑡 + 𝜓𝑑(𝐫)]𝑑𝑡𝑇0   (6) 
Where T is the acoustic period, V(r,t) is the instantaneous volume of the bubble, G(r) and 
ψ(r) are pressure and phase gradients, respectively. Because the rectified diffusion is the 
dominated effect in high frequency sonophoresis, the bubbles must be small enough to 
survive inside the skin. This means that the diffusion of molecules may not necessarily 
increase. Bommannan et al. [90] have reported that after 20 min ultrasound treatment (2 MHz, 
Compressed 
phase 
Expanded 
phase 
Liquid Shell 
Gas Gas Gas 
Equilibrium 
phase 
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0.2W/cm2), the diffusion of salicylic acid (138.12 Da) is not increased. However, the 
diffusion rate is 4 times higher at 10 MHz 0.2W/cm2 when the bubble size is small enough to 
move inside the skin. But, if the size of the bubbles is further reduced, the diffusion rate is 
dropped to 2.5 fold at frequency of 16 MHz and power of 0.2W/cm². Therefore, properly 
selected frequency will significantly increase the diffusion rate. This provides a great 
potential to deliver medium-sized or large molecules by using the microneedles and 
ultrasound combination. 
 
2.6 Acoustic cavitation in low frequency sonophoresis 
The low frequency sonophoresis generally refers to the ultrasound frequency between 20 and 
100 kHz. Unlike high frequency sonophoresis, the low frequency sonophoresis research has 
only been introduced over the last 10 years [50]. Researches showed that low frequency 
ultrasound have much better effect on drug delivery enhancement (both low and high 
molecule weight drugs) than high frequency ultrasound (beyond 1 MHz). Mitragotri et al. [63] 
have shown that the enhancement ratios induced by low-frequency ultrasound (20 KHz) is up 
to 1000-fold than that induced by therapeutic ultrasound (1 MHz) on butanol (74.12 Da) and 
sucrose (342.29 Da). This is due to the fact that inertial cavitation becomes the dominated 
mechanism and it can directly disrupt the SC layer to increase the permeability. The 
application of low-frequency ultrasound can be divided into two forms: simultaneous 
sonophoresis (decreased after ultrasound is turned off) and pre-treatment sonophoresis 
(remains in highly permeable state for several hours). The mechanisms of both of these two 
methods rely on inertial cavitation, i.e., bubbles generated within the coupling medium by 
ultrasound and would grow and collapse violently. The difference between them is the pre-
treatment sonophoresis and generates more bubbles to change the structure of the stratum 
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corneum (about 30% of the lipids layer is removed by micro-jet [91]) while the simultaneous 
sonophoresis only intends to increase the porosity.  
 
As mentioned before, the main type of cavitation which helps in permeability increment is 
the inertial cavitation [92]. It occurs due to pressure variations induced by ultrasound, 
resulting in rapid growth and collapse of bubbles formed in the coupling medium. The 
collapsing of the aforementioned bubbles in a spherically symmetric environment results in 
the release of a shockwave causing structural changes of the surrounding tissue. The suddenly 
raised pressure gradient conducted by the shockwave spreads evenly on the skin surface. 
Therefore, it can only produce limited damage. However, the skin surface will cause the 
bubbles involutes asymmetrically which results the bubbles collapse from the top surface [93]. 
Water is then forced into the bubbles and a high-speed micro-jet will be developed from the 
top surface. The power generated by the micro-jets transmits downward and is focused on a 
tiny spot of skin surface. These micro-jets can severely disrupt the SC layer and have been 
confirmed as the main contribution to the permeability increment [94]. The mechanism of 
forming micro-jets is shown in Fig. 6. 
 
Fig. 6 The mechanism of cavitation collapse near skin surface which creates a micro-jet.  
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Because of the huge bubble size in low frequency sonophoresis, the main effect is based on 
the microjet that occurs during bubbles collapse. The permeability can remain high for hours 
after a short ultrasound application. Therefore, a relatively high input power must be 
employed to create channels on the stratum corneum otherwise the permeability cannot be 
maintained. Fig. 7 indicates that insufficient power of inertial cavitation do not create 
significant pathway on the porcine stratum corneum by micro-jet. 
 
The inertial cavitation has been studied by many researchers. It shows excellent potential 
when combined with solid MNs (discussed in section 4). Solid MNs can provide 
opportunities for the inertial cavitation to physically contact the viable epidermis. It will 
greatly reduce the pretreatment time and keep the permeability increased for a longer period 
of time. These issues are discussed in detail in the following sections. 
2.7 Safety of ultrasound application 
The tolerant limit of skin to the ultrasound is an important issue for the applications of 
sonophoresis. However, only a few studies have been conducted in this area and it seems that 
this technology is still underdeveloped and has a long way to go before clinical trials. An in 
vitro study on human skin shows that at 2.5W/cm2, the skin structure modification can be 
identified under electron microscopy [70]. Although these is no in vivo study on human, 
ultrasound has been applied on canine subjects and urticarial reaction is found when the 
power reaches 16W [95]. Currently, the intensity of most sonophoresis applications are under 
3.5W/cm2 [96], so that the safety can be assured. 
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3. Microneedles (MNs) in TDD  
The MNs research has been carried out for over 40 years now and it is one of the most 
promising technologies among the TDD methods. MNs are a technology developed from 
transdermal patches and hypodermic needles, attempting to gain advantages and eliminate 
disadvantages from both. The idea of MNs comes from the patent of Gerstel and Place [97] in 
the early 1970s when they introduced the concept to make micropores in the skin. In the 
1990s, the microchip fabrication technology provided the new way to make longer three-
dimensional microstructures of silicon and mass production of microfabrication tools so that 
the experimental demonstrations can be made. The first study of using MNs to enhance TDD 
process was devoted in 1998 [98]. Following this work, MNs technology has been developed 
rapidly and greatly extended in pharmaceutical area. Compared to hypodermic needle, MNs 
are painless and can significantly reduce the pain depending on the length of the needle. Gill 
et al. [99] have  used different length of MNs from 480 µm to 1450 µm tested on human 
volunteers and found out that the needle length below 750 µm is painless and bloodless. 
However, the MNs that are less than 300 µm long have been shown not able to penetrate the 
skin [100]. The main development of the MNs technology which makes it distinct from other 
TDD methods is that it has greatly extended the range of drug molecular weight that can be 
delivered. Verbaan [101] used 700 µm MNs array to successfully deliver 
fluoresceinisothiocyanate coupled dextran which has molecular weight of 72 kDa. Influenza 
vaccine has also been delivered by using biodegradable MNs on mice [102].  
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Fig. 7 The cavitation generated by micro-jet applied on the porcine stratum corneum. A) No 
ultrasound applied on the skin; B) 20 kHz, 2.4 W/cm2 ultrasound applied on the skin for 10 
min [103] 
The MN research has developed strong activities in the last decade as indicated by a large 
number of publications. The average increment rate of MNs publications is 77.9% per year 
for the past 10 years (2004-2013) while the overall increment rate is 14.9% since 1970. To 
have a better understanding on the developing future of MNs, an ARIMA model is employed 
again which provides a rough forecast on the trend of MNs research. The data for the number 
of publications have been differenced twice to acquire a relatively stable model. The 
algorithm orders that are suitable for this model are chosen by considering the trend of 
autocorrelation coefficient and partial autocorrelation coefficient calculated from the model. 
As a result, the AR (1) and MA (1) models have been confirmed as the optimum choice with 
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minimum deviation from the original data (mean absolute percent error 139.8%).  The trend 
of MNs research until 2020 is then forecasted. After recognizing the pattern of the past 40 
years, the ARIMA model suggests that the number of publications will reach 694 in 2020 in 
comparison to 446 in 2013 which gives a 99.2% increment rate per year. The observed, fitted 
model and forecasted data have been shown in Fig.8 which suggests that in comparison to the 
trend in the past 10 years, the research in the MN area will become more active in the coming 
years. 
Fig. 8 The observed, fitted model and forecasted trend of MNs research presents from 1970 
to 2020 using ARIMA model 
There are a number of review papers focused on MNs related areas other than the 
mechanisms of MNs, for example fabrication techniques of MNs [104], permeability 
enhancement of MNs [105] and ethical study of MNs [106] etc. However, this review paper 
intends to explore the potential of MNs combined with sonophoresis. Therefore only a brief 
discussion on MNs is presented. Conventionally, MNs is divided into two different types: 
solid MNs and hollow MNs and their main mechanisms are shown in Fig. 9. 
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This classification method can only present the basic idea of the delivery process. The real 
delivery efficiency depends on many other factors. Martanto et al. [107] performed 
experiment to reveal the relationship between the MNs insertion depth and force. They also 
found out the real insertion depth is much lesser than the length of the needles due to the skin 
buckling. Their histological results shows the real penetration is only 100-300 µm by 
applying 1080 µm length MNs.  
 
Fig. 9 Main mechanisms of applying MNs: A) Solid MNs using poke with patch method; B) 
Solid MNs using coat and poke method; C) The Dissolving MNs and D) Hollow MNs for 
liquid delivery [108] 
The geometry of MNs has been proved to be another important parameter that can directly 
affect the diffusion results [109]. Parameters such as tip radius, density, distance between 
needles etc. are all brought to the consideration for being the important factors in MNs patch 
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design [110]. Besides these factors, the main purpose of MNs enhanced TDD is to reduce the 
resistance of the skin. Therefore, high force has been applied to reduce the skin buckling 
effect so that it can increase the real insertion depth [111]. Super short MNs with 70-80 µm 
length are also introduced to increase the permeability [112]. This kind of MNs is not aimed 
at penetrating the skin but to scrape the skin surface in order to lessen the thickness of SC 
layer. 
 
3.1 Solid microneedls 
The solid MNs are stiff and steady in structure and deliver drug by coated drugs on their   
surface or micro conduits created on epidermis to let drugs go through it. The methods of 
solid MNs delivery can be done in four different ways:  
(1) The poke with patch approach was proposed by Henry et al [98] who used solid MNs to 
penetrate human cadaver skin and reported that the permeability of calcein increased by up to 
three orders of magnitude. The mechanism of poke with patch method involves the use of 
solid MNs to pierce the stratum corneum first and then put a patch during the insertion or 
immediately after removal of the needles. An image is shown in Fig. 10 to illustrate this point.  
 
Fig. 10 a) Solid MNs penetrated into the skin b) after the MNs are removed, the treated skin 
is ready for applying the drug loaded patch [101] 
a b 
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Research done by Wermeling et al [113] indicated that Naltrexone (used to treat opiate and 
alcohol addiction) only takes two hours to reach the steady state plasma concentration with 
MNs pre-treatment and last for 48 hours while the transdermal patch cannot give any 
detectable results over 72 hours. Martanto et al [114] compared the hypodermic needle with 
the solid MNs (105 needles) by injecting insulin to diabetic rats and reported positive results 
on delivering large MW proteins.  
(2) The coat and poke approach is used to coat the drug on the surface of the MNs which is 
then applied on the skin (Fig. 11). Large molecules such as human growth hormone (22 kDa) 
and ovalbumin (45 kDa) can be transported through skin [115, 116] in this way.  
 
Fig. 11 Solid MNs coated with human growth hormone [115] 
The main advantage of this method is that the MNs can retain its mechanical strength while 
delivering drugs. Therefore, the permeability loss during the skin recovery can be avoided 
[117]. However, the drug reloaded during the delivery process can be a problem. The most 
efficient way is to put the matrix of MNs on a roller with coating device on one side. So the 
MNs can maintain in inserting and coating rotation when rolling on the skin surface. But this 
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method cannot increase the diffusion rate after the drug is injected which makes it faces the 
same limitation with the poke with patch approach.  
 (3) The dip and scrape method employs the array of MNs coated with drugs to treat and then 
scrape multiple times across skin to create micro-abrasions. These micro-enhancers have 
proved that they can effectively breach the skin barrier and increase the permeability of the 
drug molecules [118].  
(4) The dissolving MNs are made from a polymeric material and will release drugs after the 
MNs dissolves within skin (see Fig. 12 for an example). The main problem in this kind of 
MNs is the drug mutations during the high temperature moulding and fabrication [119]. A 
novel dissolving MNs introduced silk fibroin as the base of the MNs because it is rigid in 
structure, friendly to donor permeates and dissolving very quickly [120]. More recently, 
biopolymers have been used in the fabrications of dissolving microneedles because they can 
reduce the cost of material and also increase the biocompatibility of the products [121]. 
3.2 Hollow MNs 
The hollow MNs have similar mechanism with hypodermic needles but they are much 
smaller in size (e.g., 500 µm in length). The drugs can continuously flow into the skin 
through the hollow capillaries but in a low transmission rate. If the pressure is high the drug 
would overflow through the bypass between needle and skin to the atmosphere. One 
significant advantage of the hollow MNs among other types is that it can extract a small 
amount of blood sample underneath the skin which enables monitoring on quantities of body 
fluid, for example, blood glucose level [122]. This technology is then further developed by 
optimising the geometry and arrangement of the patch so it can give reasonable extraction 
rate [123]. Due to the small size of the hollow MNs which increase the difficulty of the 
penetration and injection, works also have been done on how to optimise the  process of MNs 
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insertion and injection pressure during drug delivery. Martanto et al [107] demonstrated that a 
little retraction during injection process can significantly increase the fluid infusion because it 
releases the compaction of the skin. The flow rate inside the hollow needles is another 
parameter that has been studied and optimised [124]. Besides the above, the stiffness of the 
MNs, difficulties in fabrication and cost are very important issues in the development of 
hollow MNs [125]. 
 
Fig. 12 The process of dissolving fibroin MNs in the porcine skin after time a) 0s, b) 15s, c) 
30s and d) 60s [120] 
4. Potential of combining MNs and sonophoresis  
This review paper focuses on discussing the ultrasound and MNs combination as a TDD 
method for the future. Therefore, we devote this section of this paper to discuss this point in 
detail. As discussed in the paper before, research on MNs and ultrasound are both actively 
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pursued in recent years, which involve different mechanisms for drug delivery and transport. 
Therefore, the main point of discussion in this section is how to combine these mechanisms. 
In addressing this issue, we discuss the different possible ways and benefits of combining 
MNs and ultrasound.    
 
We can use hollow MNs to pierce the skin and apply ultrasound simultaneously, where the 
hollow MNs should be under the ultrasound field. The hollow MNs are able to provide 
certain permeability increment while the simultaneous ultrasound field can enhance the flow 
rate via convection (this combination can be referred to the categories (iv) and (v) in Fig. 1). 
In fact, there are already some attempts to combine these two mechanisms. For example, a 
Singaporean research group has attempted this combination to deliver calcein and BSA [126]. 
They have used 100 µm long hollow MNs (80 µm outer diameter at the base) to pierce the 
skin and have attached an ultrasound transducer at the back of the MNs patch. The ultrasound 
output parameters have consisted of 20 kHz frequency, 0.5W/cm2 intensity and 20% duty 
cycles (length 10µs) which can maintain the temperature stable at 37°C. The enhancement of 
this specific circumstance shows 9 times higher for calcein and 12 times higher for BSA in 
compare to passive diffusion, respectively, as shown in Fig. 13.  
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Fig. 13 BSA release profile using simultaneous ultrasound combined with hollow MNs [126] 
We can also use solid MNs combine with ultrasound cavitation. The solid MNs can create 
visible holes that will provide permeability increment. If we apply high intensity ultrasound 
on the MNs pretreated base, the ultrasound cavitation will be able to produce more significant 
enhancement than on its own. This is because the ultrasound cavitation can contact the 
underneath layers of the skin where these bubbles can release more potentials. This 
combination is especially efficient in the delivery of large molecules and it can be a good 
preparation for a long-term TDD (this combination can be referred to the categories (iii) and 
(iv) in Fig. 1). A recent paper which has used this kind of combination to delivery BSA 
through skin is reported by Han and Das [16]. Two sets of solid MNs with length 1.2 mm and 
1.5 mm were applied for 10 min to create pores and disrupt the skin surface. The 20 kHz, 9-
18W ultrasound is then mounted to create inertial cavitation for another 10min. The 
permeability increment results of the combination in comparison with passive diffusion, 
ultrasound only and MNs only are shown in Fig.14.  
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Fig. 14 BSA permeability results of passive diffusion, ultrasound only, MNs only and MNs 
combined with ultrasound. 
It may also be possible to use solid MNs to pretreat the skin and then apply ultrasound 
simultaneously. This combination can be specialized to deliver medium size molecules. The 
difficulty in the delivery of medium size molecules is the low diffusion rate after the 
molecules have entered the viable epidermis. Solid MNs are sufficient to deliver the medium 
size molecules to the underlying layer. The simultaneous ultrasound can then apply pressure 
gradient on the molecules and achieve diffusion increment via rectified diffusion (this 
combination can be referred to the categories (iv) and (v) in Fig. 1).   
 
Furthermore, we can use dissolving MNs to pierce the skin and then apply low intensity 
simultaneous ultrasound to active the maximum thermal effect. The dissolving MNs can 
pierce into skin and release drug at a constant rate according to the local temperature. 
Ultrasound is able to provide relatively accurate local temperature adjustment. It can provide 
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temperature modification thereby controlling the drug release rate. If this combination can be 
well developed, it will achieve both drug delivery rate increment and control (this 
combination can be referred to the categories (ii) and (v) in Fig. 1).   
 
We can use high intensity ultrasound to pretreat target area and then apply dip and scrape 
MNs or super short MNs to deliver drugs. The inertial cavitation can reduce the resistance of 
SC layer so it will be easier for the MNs to create micro-abrasions on skin surface. This 
combination can provide a simple way to apply drugs that need rapid onset at topical area. 
The thermal effect comes along with the high intensity can also increase drug absorption rate 
(this combination can be referred to the categories (iii), (iv) and (v) in Fig. 1). 
 
Although the MNs combined with sonophoresis methods show significant prospects, the 
consideration of MNs combined with other TDD technologies are also equally promising. 
Therefore, a cluster analysis has been employed in this work to reveal the current trends on 
these cooperating researches. The analysis is able to make suggestions on how these trends 
are likely to develop in the future.  
 
The cluster analysis is a common statistical method used to discover useful information from 
different data groups (unlike time series analysis which uses the same time series data). The 
criteria of cluster analysis are flexible which means that it does not have a specific statistical 
algorithm [127]. In our case, four groups of subjects, namely, journal papers according to a 
specific area, are used for the analysis with 10 observations per subject counting from 2004 to 
2013. The keywords used to acquire the data of the subjects (i.e., number of papers) are (i) 
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MNs, (ii) MNs and ultrasound and phono/sonophoresis, (iii) MNs and 
iontophoresis/electroporation, (iv) MNs and chemical enhancers.  
 
We have used two specific concepts to design the clusters: the research activity and level of 
contribution from each research activity. The research activity is indicated by the number of 
publications of each year divided by the mean of the total number of publications of that 
subject group. The contribution level for each subject is defined as the number of 
publications of each year divided by the total number of publications of MNs of the same 
year. As the MNs papers cannot compare to themselves, the values of the contribution level 
of MNs are stochastically spread across the x axis. The four subjects are then plotted as four 
clusters in different shapes and colours (Fig. 15). The k-mean clustering method [128] is 
adopted to calculate the centroid of each cluster by measuring their squared Euclidean 
distance. The results of the cluster analysis (Fig. 15) indicate that both ultrasound and 
iontophoresis have shown relatively high research activities and levels of contribution. 
Specifically, the ultrasound combined with MNs shows the highest potential for research 
activity which suggests that this combination is developing fast in the past 10 years and more 
researches will be conducted in the future if the current trend continues. The iontophoresis 
and electroporation combined with MNs shows the highest contribution level which indicates 
that this is the research activity where the most current combinational researches are focused 
on.  
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Fig. 15 Cluster analysis for determining the significance of current research on combined 
MNs with other TDD technologies  
5. Conclusion 
The TDD technologies are important drug delivery methods and they are developing fast as 
reviewed and forecasted in this paper. The idea of ultrasound and MNs combination is 
relatively new but shows a promising future. The forms and design of MNs patches will be 
more diverse in the future. Given that portable ultrasound instrument is a common medical 
device in hospitals, a patient friendly design of the combination are likely to be achieved at a 
reasonable cost when this concept is matured enough.  
In order to discuss the scope of combined MNs and ultrasound research, this review paper has 
introduced the relevant mechanisms of MNs and sonophoresis as well as pointed out the 
weak areas in the researches of these two technologies. By working on those weak areas, 
more combinational approaches can be developed, particularly when the ultrasound and MNs 
are more developed as methods. Although the combination of MNs and ultrasound seems to 
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make TDD more complicated, it is a necessary step to achieve both higher and controllable 
drug delivery rate. In conclusion, we must state that the MNs and ultrasound combination has 
a promising future to solve some of the current problems in TDD.  
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